收费全文 | 293930篇 |
免费 | 17232篇 |
国内免费 | 392篇 |
耳鼻咽喉 | 4200篇 |
儿科学 | 10245篇 |
妇产科学 | 10164篇 |
基础医学 | 44698篇 |
口腔科学 | 7480篇 |
临床医学 | 23795篇 |
内科学 | 55093篇 |
皮肤病学 | 6303篇 |
神经病学 | 20883篇 |
特种医学 | 11593篇 |
外国民族医学 | 43篇 |
外科学 | 46522篇 |
综合类 | 7713篇 |
一般理论 | 160篇 |
预防医学 | 19692篇 |
眼科学 | 6933篇 |
药学 | 20793篇 |
中国医学 | 739篇 |
肿瘤学 | 14505篇 |
2018年 | 3548篇 |
2017年 | 2627篇 |
2016年 | 3046篇 |
2015年 | 3450篇 |
2014年 | 4557篇 |
2013年 | 7186篇 |
2012年 | 9060篇 |
2011年 | 9436篇 |
2010年 | 6118篇 |
2009年 | 5530篇 |
2008年 | 8654篇 |
2007年 | 9506篇 |
2006年 | 9350篇 |
2005年 | 8948篇 |
2004年 | 8658篇 |
2003年 | 8149篇 |
2002年 | 7742篇 |
2001年 | 13316篇 |
2000年 | 13627篇 |
1999年 | 11348篇 |
1998年 | 2884篇 |
1997年 | 2615篇 |
1996年 | 2478篇 |
1995年 | 2538篇 |
1994年 | 2338篇 |
1992年 | 8306篇 |
1991年 | 8452篇 |
1990年 | 8261篇 |
1989年 | 8076篇 |
1988年 | 7310篇 |
1987年 | 7074篇 |
1986年 | 6719篇 |
1985年 | 6515篇 |
1984年 | 4753篇 |
1983年 | 4112篇 |
1982年 | 2458篇 |
1979年 | 4415篇 |
1978年 | 3219篇 |
1977年 | 2723篇 |
1976年 | 2485篇 |
1975年 | 2823篇 |
1974年 | 3348篇 |
1973年 | 3357篇 |
1972年 | 3112篇 |
1971年 | 2948篇 |
1970年 | 2832篇 |
1969年 | 2579篇 |
1968年 | 2535篇 |
1967年 | 2371篇 |
1966年 | 2259篇 |
Vaccination prevents severe morbidity and mortality from COVID-19 in the general population. The immunogenicity and efficacy of SARS-CoV-2 vaccines in patients with antibody deficiency is poorly understood.
ObjectivesCOVID-19 in patients with antibody deficiency (COV-AD) is a multi-site UK study that aims to determine the immune response to SARS-CoV-2 infection and vaccination in patients with primary or secondary antibody deficiency, a population that suffers from severe and recurrent infection and does not respond well to vaccination.
MethodsIndividuals on immunoglobulin replacement therapy or with an IgG less than 4 g/L receiving antibiotic prophylaxis were recruited from April 2021. Serological and cellular responses were determined using ELISA, live-virus neutralisation and interferon gamma release assays. SARS-CoV-2 infection and clearance were determined by PCR from serial nasopharyngeal swabs.
ResultsA total of 5.6% (n?=?320) of the cohort reported prior SARS-CoV-2 infection, but only 0.3% remained PCR positive on study entry. Seropositivity, following two doses of SARS-CoV-2 vaccination, was 54.8% (n?=?168) compared with 100% of healthy controls (n?=?205). The magnitude of the antibody response and its neutralising capacity were both significantly reduced compared to controls. Participants vaccinated with the Pfizer/BioNTech vaccine were more likely to be seropositive (65.7% vs. 48.0%, p?=?0.03) and have higher antibody levels compared with the AstraZeneca vaccine (IgGAM ratio 3.73 vs. 2.39, p?=?0.0003). T cell responses post vaccination was demonstrable in 46.2% of participants and were associated with better antibody responses but there was no difference between the two vaccines. Eleven vaccine-breakthrough infections have occurred to date, 10 of them in recipients of the AstraZeneca vaccine.
ConclusionSARS-CoV-2 vaccines demonstrate reduced immunogenicity in patients with antibody deficiency with evidence of vaccine breakthrough infection.
相似文献